Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6 Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?

de Joode Karlijn; van der Veldt Astrid A. M.

首页> 外文期刊>European urology >Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6 Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?

【24h】

Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6 Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?

机译：回复：劳伦斯·山顶，汤姆鲍尔斯，Michael Staehler等。更新欧洲泌尿外科协会肾细胞癌：免疫检查点抑制是一种新的骨干，在第一线治疗转移性透明细胞肾细胞癌。 2019年EUR UROL; 76：151-6转移性肾细胞癌症的主动监测：缺少治愈机会？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2020年第3期|共2页
作者
de Joode Karlijn; van der Veldt Astrid A. M.;
展开▼
作者单位

Erasmus MC Canc Inst Dept Med Oncol Dr Molewaterpl 40 NL-3015 GD Rotterdam Netherlands;

Erasmus MC Canc Inst Dept Med Oncol Dr Molewaterpl 40 NL-3015 GD Rotterdam Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献

1. Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6 Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure? [J] . de Joode Karlijn, van der Veldt Astrid A. M. European urology . 2020,第3期

机译：回复：劳伦斯·山顶，汤姆鲍尔斯，Michael Staehler等。更新欧洲泌尿外科协会肾细胞癌：免疫检查点抑制是一种新的骨干，在第一线治疗转移性透明细胞肾细胞癌。 2019年EUR UROL; 76：151-6转移性肾细胞癌症的主动监测：缺少治愈机会？
2. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Mejean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3 Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma [J] . Santoni Matteo, Montironi Rodolfo, Battelli Nicola, European urology . 2019,第3期

机译：回复Michael Staehler，Dena Battle，Axel Bex，Hans Hammers和Daniel George的信Re：Arnaud Mejean，Alain Ravaud，Simon Thezenas，等。单独的Sunitinib或在转移性肾细胞癌中肾切除术后。 EUR UROL 2018; 74：842-3淋巴细胞表型和自由基肾切除术治疗肾细胞癌治疗的患者的激进肾切除术
3. Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041 Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment? [J] . Giuliani Jacopo, Bonetti Andrea European urology . 2018,第3期

机译：Re：Michal Sarfaty，Moshe Leshno，Noa Gordon等。晚期肾细胞癌中Nivolumab的成本效果。 EUR UROL。在新闻。 http://dx.doi.org/10.1016/j.eururo.2017.07.041二线治疗转移性肾细胞癌。可以免疫疗法被认为是具有成本效益的治疗方法吗？
4. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
5. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET) [O] . Toni K. Choueiri, Suchun Cheng, Angela Q. Qu, -1

机译：碳酸酐酶IX如转移性透明细胞肾细胞癌患者的疗效的生物标记物的潜在接受索拉非尼或安慰剂：分析从治疗肾癌全球评价试验方法（TaRGET）
6. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma [O] . Laurence Albiges, Tom Powles, Michael Staehler, 2019

机译：更新欧洲泌尿外科协会肾细胞癌：免疫检查点抑制是转移性透明细胞肾细胞癌的一线治疗中的新骨干

著录项

相似文献

相关主题

期刊订阅